Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci official news RSS · Indexed industry source record · Source published: Wed Jun 24 2026 10:30:27 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:26 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.